Freenome (NASDAQ:FRNM) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Freenome (NASDAQ:FRNM) to a sell rating in a research report released on Saturday,Wall Street Zen reports.

A number of other equities analysts also recently issued reports on FRNM. Guggenheim started coverage on Freenome in a research note on Thursday, August 20th. They issued a “buy” rating and a $21.00 price target on the stock. BTIG Research assumed coverage on Freenome in a research report on Monday, August 17th. They set a “buy” rating and a $17.00 price objective for the company. Weiss Ratings initiated coverage on Freenome in a report on Monday, August 24th. They issued a “sell (d+)” rating on the stock. Jefferies Financial Group assumed coverage on Freenome in a report on Monday, August 17th. They issued a “buy” rating and a $17.00 target price on the stock. Finally, Leerink Partners began coverage on Freenome in a research report on Friday, August 14th. They issued an “outperform” rating and a $18.00 target price on the stock. Five research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $18.00.

Freenome Stock Up 1.3%

NASDAQ:FRNM opened at $16.19 on Friday. Freenome has a 12 month low of $9.97 and a 12 month high of $17.50. The company has a market capitalization of $1.74 billion, a price-to-earnings ratio of -269.79 and a beta of 0.48.

About Freenome

Freenome is a biotechnology company developing blood-based tests designed to detect cancer at earlier, more treatable stages. Its approach combines artificial intelligence with multiomics analysis, examining biological signals in blood, including circulating tumor material and other molecular indicators.

The company has focused on noninvasive screening tests for colorectal cancer and other cancers. Freenome’s products remain in development and are being evaluated through clinical research and validation studies; the company’s tests are not described here as broadly approved diagnostic products.

Founded in 2014 and headquartered in the United States, Freenome has worked with healthcare providers, research organizations and pharmaceutical companies to advance its screening technology.